Orforglipron在选定GLP-1受体激动剂基准药物中的比较定位：一项叙述性综述
Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.
摘要(中文译文)
Orforglipron是一种口服非肽类小分子胰高血糖素样肽-1受体激动剂，开发用于2型糖尿病和肥胖症。本叙述性综述通过整合结构、药理学、临床和实践证据，评估其在已上市GLP-1受体激动剂中的比较定位。采用叙述性文献综述方法，检索PubMed/MEDLINE、Embase、Scopus、Web of Science、ClinicalTrials、官方处方信息及引文追踪。综合归纳按比较维度组织，包括分子结构、受体药理学、早期临床药理学、直接比较证据、背景对照证据及实际给药。从筛选的245条记录中，去除88条重复记录，评估157条唯一记录，最终保留35篇以orforglipron为重点的文献来源。通过针对性引文验证，另选取7项对照试验，因其代表了2型糖尿病和肥胖症中口服司美格鲁肽、另一种口服小分子GLP-1受体激动剂danuglipron以及作为高效类比较药物的注射用司美格鲁肽的临床相关基准。当前证据确定了与orforglipron比较定位相关的若干维度，包括其非肽类小分子结构、受体药理学、每日一次口服给药特征，以及针对度拉糖肽和口服司美格鲁肽的直接比较证据。食物效应和处方信息来源显示，orforglipron的食品相关给药限制少于口服司美格鲁肽。然而，间接比较仍受人群、剂量、随访时长、对照药物和终点差异的限制。目前，orforglipron应被视为一种具有新兴比较证据的口服小分子GLP-1受体激动剂，而非现有药物的广泛优越替代品。仍需进一步的长期比较、心血管、肾脏、安全性、依从性及真实世界有效性数据，以确定其最终治疗地位。
Abstract
Orforglipron is an oral, nonpeptide, small-molecule glucagon-like peptide-1 receptor agonist developed for type 2 diabetes and obesity. This narrative review evaluates its comparative positioning among marketed GLP-1 receptor agonists by integrating structural, pharmacological, clinical, and practical evidence. A narrative literature review was conducted using PubMed/MEDLINE, Embase, Scopus, Web of Science, ClinicalTrials, official prescribing information, and citation tracking. The synthesis was organized by comparative domains, including molecular structure, receptor pharmacology, early clinical pharmacology, direct comparative evidence, contextual comparator evidence, and practical administration. From 245 screened records, 88 duplicates were removed, 157 unique records were assessed, and 35 orforglipron-focused sources were retained. Seven additional comparator trials were selected through targeted citation verification because they represented clinically relevant benchmarks for oral semaglutide in type 2 diabetes and obesity, danuglipron as another oral small-molecule GLP-1 receptor agonist, and injectable semaglutide as a high-efficacy class comparator. Current evidence identifies several domains relevant to the comparative positioning of orforglipron, including its nonpeptide small-molecule structure, receptor pharmacology, once-daily oral dosing profile, and direct comparator evidence against dulaglutide and oral semaglutide. Food-effect and prescribing-information sources describe fewer food-related administration constraints for orforglipron than for oral semaglutide. However, indirect comparisons remain limited by differences in populations, doses, follow-up duration, comparators, and endpoints. At present, orforglipron should be viewed as an oral small-molecule GLP-1 receptor agonist with emerging comparative evidence, rather than as a broadly superior replacement for existing agents. Further long-term comparative, cardiovascular, renal, safety, adherence, and real-world effectiveness data are needed to define its final place in therapy.
如何引用
AMA
José Castro-Gamboa, Jeaustin Mora-Jiménez, Sebastián Arguedas-Chacón, Esteban Zavaleta-Monestel. Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.. Cureus. 2026; doi:10.7759/cureus.110178.
APA
José Castro-Gamboa, Jeaustin Mora-Jiménez, Sebastián Arguedas-Chacón, Esteban Zavaleta-Monestel (2026). Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.. Cureus. https://doi.org/10.7759/cureus.110178
GB/T 7714
José Castro-Gamboa, Jeaustin Mora-Jiménez, Sebastián Arguedas-Chacón, Esteban Zavaleta-Monestel. Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.[J]. Cureus, 2026 doi:10.7759/cureus.110178.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出